Handok’s DPP-4 inhibitor ‘Tenelia’ sales reach 10 billion
won

-Good efficacy of Tenelia and Handok’s leadership in diabetes market lead
to the achievement of such outstanding result before 1 year of launching

-The ‘matching
grant campaign’ is planned to take place, where fund will be accumulated for
every message of support for diabetes patient

Tenelia, a potent DPP-4 inhibitor by Handok has reached
cumulative sales figure of 10 billion won, according to Handok’s own sales
count. Following the launch of Tenelia (active ingredient: Teneligliptin) last
August, Handok also launched Tenelia M SR tablets (active ingredient:
Teneligliptin + Metformin) in October, where the company was able to achieve
sales of 10 billion won for the two products combined before 1 year of
launching.

The critical success factor for Tenelia lies in its
potent antidiabetic effect, allowing 7 out of 10 diabetic patients to reach
their target HbA1c of < 7.0%. Tenelia allows outstanding number of its patients to reach their target blood glucose, as well as offering the convenience of once daily dosing which provides sufficient postprandial blood glucose control even after dinner. There is also the extra advantage of not needing to adjust dose for any renal impairment patients. For the combination tablet Tenelia M SR, the tablet size was able to be minimized by adopting the DRM(Dual Release Micro-coating) technology, which greatly enhanced patient adherence.

Handok’s leadership in the Korean diabetes market which
accumulated over time also played an important role in Tenelia’s success. Since
launching the antidiabetic drug ‘Daonil’ in 1973, Handok turned itself to a ‘company
that offers a total solution for diabetes’ over the last 50 years. Handok
produces antidiabetic drug ‘Tenelia’ and ‘Amaryl’, as well as blood glucose
monitor ‘Barojan’. Handok was also the first company to adopt diabetes care education
program in the field. Since 2009, Handok has held the <Confident
steps campaign>, a social contribution event which hopes to make diabetes
patients more aware of the importance of foot care.

President Youngjin Kim of Handok commented that “Although
Tenelia may be the 7^th DPP-4 inhibitor to be launched in Korea, with
its strong antidiabetic effect and Handok’s long business experience in
diabetes, it will sure to grow fast’. He also proudly mentioned that “Handok’s
reputation that was built on Amaryl’s success will be continued with Tenelia.”

Handok will conduct the campaign
over the month of August to celebrate for Tenelia’s growth and success. In this
campaign, Handok will accumulate 5 thousand won for every message of support
that a health care professional sends to a diabetes patient. The accumulated
fund will be added to this year’s to provide
diabetic shoes to more diabetes patients.